Desidustat (INN, also known asZYAN1) is adrug for the treatment ofanemia ofchronic kidney disease. This drug with the brand nameOxemia is discovered and developed by Zydus Life Sciences.[1]
Desidustat reduces the requirement of recombinant erythropoietin (EPO) in anemia, and decreases EPO-resistance, by reducing IL-6, IL-1β, and anti-EPO antibodies.[2]
Desidustat has been studied for use in conditions beyond anemia of chronic kidney disease, including chemotherapy-induced anemia, inflammation-induced anemia, and acute kidney injury. It is also being evaluated in clinical trials for sickle cell disease and has been suggested as a treatment for complement-mediated diseases and stroke in chronic kidney disease patients.[4]
The subject expert committee of CDSCO has recommended the grant of permission for manufacturing and marketing of Desidustat 25 mg and 50 mg tablets in India, based on some conditions related to package insert, phase 4 protocols, prescription details, and GCP.[5]
Zydus Lifesciences and Sun Pharmaceuticals have entered an agreement in October 2023 to co-market Desidustat. Sun Pharma will sell the drug asRytstat, while Zydus will continue to sell it asOxemia.[6]
^Kaur H, Pandey N, Chandaluri L, Shaaban N, Martinez A, Kidder E, et al. (February 2025). "Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease".Experimental Neurology: 115181.doi:10.1016/j.expneurol.2025.115181.
